Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Adenosine Receptor A3 (ADORA3) - Overview Adenosine Receptor A3 (ADORA3) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development Can-Fite BioPharma Ltd Adenosine Receptor A3 (ADORA3) - Drug Profiles ACN-1052 - Drug Profile Product Description Mechanism Of Action R&D Progress CF-602 - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile Product Description Mechanism Of Action R&D Progress FM-101 - Drug Profile Product Description Mechanism Of Action R&D Progress FM-1101 - Drug Profile Product Description Mechanism Of Action R&D Progress FM-1102 - Drug Profile Product Description Mechanism Of Action R&D Progress FM-1103 - Drug Profile Product Description Mechanism Of Action R&D Progress FM-1202 - Drug Profile Product Description Mechanism Of Action R&D Progress FM-1203 - Drug Profile Product Description Mechanism Of Action R&D Progress FM-1301 - Drug Profile Product Description Mechanism Of Action R&D Progress FM-1302 - Drug Profile Product Description Mechanism Of Action R&D Progress LJ-1888 - Drug Profile Product Description Mechanism Of Action R&D Progress LJ-2698 - Drug Profile Product Description Mechanism Of Action R&D Progress namodenoson - Drug Profile Product Description Mechanism Of Action R&D Progress PBF-1650 - Drug Profile Product Description Mechanism Of Action R&D Progress PBF-677 - Drug Profile Product Description Mechanism Of Action R&D Progress piclidenoson - Drug Profile Product Description Mechanism Of Action R&D Progress Adenosine Receptor A3 (ADORA3) - Dormant Products Adenosine Receptor A3 (ADORA3) - Discontinued Products Adenosine Receptor A3 (ADORA3) - Product Development Milestones Featured News & Press Releases Feb 28, 2018: Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Piclidenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Namodenoson to FDA and other Regulatory Authorities Feb 12, 2018: Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson Jan 25, 2018: Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries Dec 18, 2017: Can-Fite Reports on the Progress of Its Phase II Liver Cancer with Namodenoson Nov 27, 2017: Can-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson Oct 30, 2017: Can-Fite Announces Enrollment of First Patient in its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis Oct 17, 2017: Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis Oct 16, 2017: Can-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, D.C. Oct 09, 2017: Can-Fite CEO Dr. Pnina Fishman to Present as Expert Speaker at NASH Summit Europe in Frankfurt, Germany on October 12, 2017 Aug 23, 2017: Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea Aug 09, 2017: Can-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer Aug 07, 2017: Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson Jul 17, 2017: Can-Fite's Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Can-Fite BioPharma Ltd, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Discontinued Products, H1 2018List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018